Immune tolerance therapy for factor VIII inhibitors: Moving from empiricism to an evidence-based approach

Journal of Thrombosis and Haemostasis

Volumn 5, Issue SUPPL. 1, 2007, Pages 143-150

  Dimichele, Donna ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b New York Weill Cornell Center   (United States)

Author keywords

Factor VIII; Hemophilia A; Immune tolerance; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; FACTANE; IMMUNOGLOBULIN; INTERLEUKIN 10; MONOCLONAL ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTIGEN SPECIFICITY; ARTERIOVENOUS FISTULA; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG INDUCED DISEASE; EMPIRICISM; EVIDENCE BASED MEDICINE; GENE TRANSFER; HEMARTHROSIS; HEMOPHILIA A; HOST; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFECTION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SERUM SICKNESS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICE;

EMPIRICAL RESEARCH; FACTOR VIII; HUMANS; IMMUNE TOLERANCE; SERINE PROTEINASE INHIBITORS;

EID: 34250712964     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02474.x     Document Type: Review

References (73)

1. Brackmann HH, Gormsen J. Massive factor-VIII infusion in hemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 29: 93.
2. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of FVIII inhibitors - twenty years of the Bonn protocol. Vox Sang 1996; 70 (Suppl.): 30-5.
3. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg BM, Nilsson IM. Tolerance induction using the Malmötreatment model 1982-1995. Haemophilia 1999; 5: 32-9.
4. Smith MP, Spence KJ, Waters EL, Beresford-Webb R, Mitchell MJ, Cuttler J, Alhaq A, Brown SA, Savidge GF. Immune tolerance therapy for hemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999; 8: 35-8.
5. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, deBiasi R. Immune tolerance induction in hemophilia A patients with high-responding inhibitors to factor VIII: Experience at a single institution. Haemophilia 2001; 7: 33-8.
6. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briet E, van den Berg HM. Clinical course of factor VIII inhibitors developed after exposure to a pasteurized Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemos 1994; 71: 703-6.
7. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992; 14: 82-7.
8. Mariani G, Scheibel E, Nogao T, Kasper CK, Ewing NP, Mauser-Bunschoten E, Ghirardini A, Bellocco R, Brackmann HH. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 1994; 31(Suppl 4): 62-4.
9. Lenk H; ITT Study Group. The German Registry of immune tolerance treatment in hemophilia-1999 update. Haematologica. 2000; 10(Suppl): 45-7.
10. DiMichele DM, Kroner B and the North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
11. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: A review. Semin Thromb Hemost. 2003; 29: 69-76.
12. Consensus Proceedings from the Second International Conference on Immune Tolerance Therapy. Bonn, Germany: 1997 (unpublished).
13. DiMichele D, Kroner B; Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: The North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Haemostasis. Haematologica 2000; 85(Suppl 10): 40-4.
14. DiMichele DM, Hay CRM. The international immune tolerance study: A multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271-3.
15. Astermark J, Morado M, Rocino A, Vandenberg HM, Von Depka M, Gringeri A, Mantovani L, Garrido RP, Schiavoni M, Villar A, Windyga J. Current European practice in immune tolerance induction therapy in patients with heamophilia and inhibitors. Haemophilia 2006; 12: 363-71.
16. Astermark J, Oldenburg J, Escobar M, White GC II, Berntorp E MalmöInternational Brother Study Group. The MalmöInternational Brother Study (MBIS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90: 924-31.
17. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Re 1984; 150: 19-29.
18. Addiego JR Jr, Kasper C, Abildgaard C, et al. Increased frequency of inhibitors in African American hemophilia A patients [Abstract]. Blood 1994; 1: 239a.
19. Oldenburg J, Pavlova A. Genetic Risk Factors for inhibitors to factor VIII and IX Haemophilia 2006; 12 (Suppl 6): 15-22.
20. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL-10 but not in the IL-1β and IL-4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
21. Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK, for the MIBS Study Group. Polymorhisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
22. Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 2006; 91: 558-61.
23. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in hemophilia A. Inhibitor patients by the 'Bonn Protocol': Predictive Parameters for Therapy, Duration & Outcome. Vox Sang 1999; 77 (Suppl 1): 49-54.
24. Mariani G, Kroner B. Immune tolerance in hemophilia with factor VIII inhibitors: Predictors of success. Haematologica 2001; 86: 1186-993.
25. Kroner BL. Comparison of the International Immune Tolerance Registry and the North American Immune Tolerance Registry. Vox Sang 1999; 77(Suppl.1): 33-7.
26. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
27. Barnes C, Rivard GE, Poon MC, Teitel J, Pai M, Kern M, Blanchette VS, Carcao M; Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada.. Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT. Haemophilia 2006; 12: 1-6.
28. Lusher JM. Summary of clinical experience with recombinant factor VIII products-Kogenate. Ann Hematol 1994; 68(Suppl 3): S3-6.
29. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G III, Lee M; The Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-35. 83: 2428-35.
30. Batlle J, Lopez MF, Brackmann HH, Gaillard S, Goudemand J, Humbert J, De Mooerloose P, Maass E, Mauz-Korholz C, Sultan Y, Stieltjes N. Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. Haemophilia 1999; 5: 431-5.
31. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38 (Suppl 4): 52-9.
32. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 1: 27-31.
33. DiMichele D, Kroner B. Higher Immune Tolerance (IT) success rate with monoclonal FVIII (mFVIII) when compared to recombinant (rFVIII): An analysis of The North American Immune Tolerance Registry (NAITR) [Abstract]. Blood 2000; 96: 266a.
34. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 2000; 6: 150-7.
35. Damiano ML, Hutter JJ Jr. Immune tolerance for haemophilia patients with inhibitors: Analysis of the western United States experience. The Tri-Regional Nursing Group. Haemophilia 2000; 6: 526-32.
36. Saenko EL, Ananyeva NM, Kouiavskaia DV, Khrenov AV, Anderson JA, Shima M, Qian J, Scott D. Hemophilia A: Effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Hemophilia 2002; 8: 1-11.
37. Salvagno GL, Astermark J, Ekman M, Franchini M, Guidi GC, Lippi G, Poli G, Berntorp E. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 51-6.
38. Dasgupta S, Repesse Y, Bayry J, Navarrete AM, Wootla B, Delignant S, Irinopoulou T, Kamate C, Saint-Remy SM, Jacquenim M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix- Desmazes S. Brief report VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.
39. Reding MT. Immunological aspects of inhibitor development. Haemophilia 2006; 12(Suppl. 6): 30-6.
40. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50.
41. Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia. Malmöprotocol update. Haematologica 2000; 85: 48-50.
42. Rivard GE, St Louis J, Lacroix S, Champagne M, Rock G. Immunoadsorption for coagulation factor inhibitors: A retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003; 9: 711-6.
43. Franchini M, Veneri D, Lippi G, Stenner R. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 2006; 96: 119-25.
44. Stachnik JM. Rituximab in the treatment of acquired hemophilia. Ann of Pharmacother 2006; 40: 1151-7.
45. Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 2007; 92: 66-71.
46. Collins PW. Novel Therapies for Immune Tolerance in Haemophilia A. Haemophilia 2006; 12(Suppl. 6): 94-101.
47. Reipert BM, van den Helden PMW, Schwarz HP, Causl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2006; 136: 12-25.
48. Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang L, Hertzog RW. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induces regulatory T cells. Proc Natl Acad Sci USA 2006; 103: 4592-7.
49. Ashrani AA, Reding MT, Shet A, Osip J, Humar A, Lake JR, Key NS. Successful liver transplantation in a patient with severe haemophilia A and a high titre factor VIII inhibitor. Haemophilia 2004; 10: 735-7.
50. Tarantino MD, Lail A, Donfield SM, Lynn H, Peddle L, Hunsberger S, Shapiro AD. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003; 9: 588-92.
51. Ljung R. Central venous lines in haemophilia. Haemophilia 2003; 9 (Suppl 1): 88-92.
52. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia. 2004; 10: 134-46.
53. Franchini M. Thrombotic complications in patients with hereditary bleeding disorders. Thromb Haemost 2004; 92: 298-304.
54. Ewenstein BM, Valentino LA, Journeycake JM, Tarantino MD, Shapiro AD, Blanchette VS, Hoots WK. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10: 629-48.
55. Crary SE, Buchanan GR, Journeycake JM. Fatal central venous catheter-related infection in haemophilia. Haemophilia 2006; 12: 183-6.
56. van den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. The use of the Port-A-Cath in children with haemophilia-a review. Haemophilia 1998; 4: 418-20.
57. Santagostino E, Gringeri A, Berardinelli L, Beretta C, Muca-Perja M, Mannucci PM. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: A prospective study. Br J Haematol 2003; 123: 502-6.
58. Soucie JM, Cianfrini C, Janco RL, Kulkarni R, Hambleton J, Evatt B, Forsyth A, Geraghty S, Hoots K, Abshire T, Curtis R, Forsberg A, Huszti H, Wagner M, White GC II. Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors. Blood 2004; 103: 2467-73.
59. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIS Study Group. Blood 2003; 102: 2358-63.
60. Manco-Johnson MJ, Abshire TC, Brown D, Buchanan GR, Cohen AR, DiMichele D, Hoots WK, Leissinger CA, McRedmond K, Nugent DJ, Shapiro AD, Thomas GA, Valentino LA, Riske B. Initial Results of a Randomized, Prospective Trial of Prophylaxis To Prevent Joint Disease in Young Children with Factor VIII (FVIII) Deficiency [Abstract]. Blood 2005; 106: 3.
61. Di Paolo J, Aledort L, Britton H, Carcao M, Grabowski E, Hutter J, Journeycake J, Kempton C, Leissinger C. Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia 2006; 12: 591-7.
62. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Hemophilia 2003; 9: 261-8.
63. Kreuz W, Escuriola-Ettingshausen C, Mentzer D, et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors [Abstract]. Blood 2000; 96: 266a.
64. Carcao MD, Connolly BL, Chait P, Stain AM, Acebes M, Massicotte P, Blanchette VS. Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia 2003; 5: 578-83.
65. Konkle BA, Ebbesen LS, Friedrich U, et al. Secondary prophylactic treatment with rFVIIa in patients with haemophilia A or B and inhibitors with high requirements for on-demand treatment: Analysis of primary endpoint and safety. Poster presented at: XXVII International Congress of the World Federation of Hemophilia; May 21-25; 2006; Vancouver, Canada. Haemophilia 2006; 12 (Suppl. 2): 57-69.
66. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-7.
67. Brackmann HH, Effenberger E, Hess L, Schwaab R, Oldenburg J. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis. 2000; 11(Suppl 1): S39-44.
68. Hay CRM, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
69. Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
70. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM. Inhibitors to factor VIII in a family with mild hemophilia: Molecular characterization and response to factor VIII and desmopressin. Thromb Haemost. 1995; 74: 619-21.
71. Robbins D, Kulkarni R, Gera R, Scott-Emuakpor AB, Bosma K, Penner JA. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol. 2001; 68: 184-8.
72. Vlot AJ, Wittebol S, Strengers PF, Turenhout EA, Voorberg J, van den Berg HM, Mauser-Bunschoten EP. Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618- > Ser mutation responsive to immune tolerance induction and cyclophosphamide. Br J Haematol 2002; 117: 136-40.
73. D'Oiron R, Volot F, Reynaud J, Peerlinck K, Goudemand J, Guerois C, Rothschild C, Chambost Borel-Derlon A, Roussel-Robert V, Marques-Verdier A, Lienhard A, Berthier AM, Moreau P, Lambert T; MHAI Study Group. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia A and inhibitors. Semin Hematol 2006; 43: S3-9.